PF-Atlas › Clinical Trials › NCT07720375
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Galvokimig · Phase 2
Registry ID
NCT07720375
Phase
Phase 2
Status
Not yet recruiting
Drug / intervention
Galvokimig
Sponsor
UCB Biopharma SRL
Start
2026-07-31
Enrollment
300
Locations
3
About this trial
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07720375 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.